These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25501616)

  • 1. Models for predicting effective HIV chemoprevention in women.
    Nicol MR; Emerson CW; Prince HM; Nelson JA; Fedoriw Y; Sykes C; Geller EJ; Patterson KB; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):369-76. PubMed ID: 25501616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
    Veselinovic M; Yang KH; LeCureux J; Sykes C; Remling-Mulder L; Kashuba ADM; Akkina R
    Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
    Dobard CW; Taylor A; Sharma S; Anderson PL; Bushman LR; Chuong D; Pau CP; Hanson D; Wang L; Garcia-Lerma JG; McGowan I; Rohan L; Heneine W
    J Infect Dis; 2015 Dec; 212(12):1988-95. PubMed ID: 26071566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
    Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN
    PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
    Tiraboschi JM; Niubo J; Curto J; Podzamczer D
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):606-9. PubMed ID: 20706127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.
    Herrera C; Armanasco N; García-Pérez J; Ziprin P; Olejniczak N; Alcamí J; Nuttall J; Shattock RJ
    AIDS; 2016 Apr; 30(7):1015-25. PubMed ID: 26854808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
    Moss JA; Butkyavichene I; Churchman SA; Gunawardana M; Fanter R; Miller CS; Yang F; Easley JT; Marzinke MA; Hendrix CW; Smith TJ; Baum MM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3759-66. PubMed ID: 27067321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
    Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.
    Louissaint NA; Cao YJ; Skipper PL; Liberman RG; Tannenbaum SR; Nimmagadda S; Anderson JR; Everts S; Bakshi R; Fuchs EJ; Hendrix CW
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1443-50. PubMed ID: 23600365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
    Clark MR; Friend DR
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
    Baheti G; King JR; Acosta EP; Fletcher CV
    AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
    García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
    J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
    Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
    J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
    Sepúlveda-Crespo D; Sánchez-Rodríguez J; Serramía MJ; Gómez R; De La Mata FJ; Jiménez JL; Muñoz-Fernández MÁ
    Nanomedicine (Lond); 2015; 10(6):899-914. PubMed ID: 25867856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
    Fang J; Jadhav PR
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):357-68. PubMed ID: 22736302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.
    Rosario MC; Poland B; Sullivan J; Westby M; van der Ryst E
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):183-91. PubMed ID: 16639345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
    AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
    Johnson TJ; Clark MR; Albright TH; Nebeker JS; Tuitupou AL; Clark JT; Fabian J; McCabe RT; Chandra N; Doncel GF; Friend DR; Kiser PF
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6272-83. PubMed ID: 23006751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.
    McGowan I; Wilkin T; Landovitz RJ; Wu C; Chen Y; Marzinke MA; Hendrix CW; Richardson P; Eshleman SH; Andrade A; Chege W; Anderson PL; McCauley M; Farley J; Mayer KH; Anton P; Brand RM; Cranston RD; Gulick R
    AIDS; 2019 Feb; 33(2):237-246. PubMed ID: 30557160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.